Diabetes mellitus (DM) is an epidemic disease, with approximately 463 million persons diagnosed with it. Of those, 90% are patients with type 2 DM (T2DM). Some estimates indicate that 700 million cases of DM will be reported in 2045. T2DM develops due to insulin resistance, leading to reduced insulin secretion. DM has a number of associated complications, such as nephropathy, neuropathy, and cardiovascular disease.
Patients diagnosed to have Uncontrolled type 2 diabetes mellitus (HbA1C more than 7%)
Patients diagnosed to have type 1 diabetes.
Patients are diagnosed to have secondary diabetes.
Anemia (Female Hb less than 12, Male Hb less than 13) either due to hemolysis, or in response to ineffective red cell production, which can be caused by deficiencies in iron, vitamin B12 or folate.
After blood transfusions
Patients diagnosed to have type 2 diabetes
Case-control
Prospective
Glycated hemoglobin (HbA1C)
Diagnostic testBlood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
RDW
Diagnostic testBlood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
Lipid profile
Diagnostic testBlood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
To assess the correlation between RDW and HbA1C levels in patients with T2DM before and after glycemic control.
To determine if changes in RDW levels correlate with the presence of other comorbidities and complications.
Click on the lead sponsor to view all of their trials.
